drug

azilsartan kamedoxomil

Marketedupdated 2mo ago

by Azurity Pharmaceuticals Inc

Approved

community read0 votes

indications

investigational

Hypertension

all catalysts(0)

nothing on the calendar yet

News(0)

no news has mentioned this drug yet

Patent cliff

source: FDA Orange Book

first barrier falls

Mar 26, 2028

~1.7 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (2)

Mar 26, 2028formulationUS 90669361.7y
Mar 26, 2028formulationUS 90669361.7y

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Data sources

ClinicalTrials.gov

last refreshed 1h ago

Found something off?

Trials studying azilsartan kamedoxomil

phase1Bioequivalence Study of Azilsartan Medoxomil 80 mg Tablets (Gedeon Richter Plc., Hungary) and Edarbi® 80 mg Tablets (JSC Nizhpharm, Russia)not yet recruitingn=56